Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones

In Vivo

Volumn 21, Issue 3, 2007, Pages 445-452

  Vesely, David L ^a,b   Eichelbaum, Ehrentraud J ^a   Sun, Ying ^a   Alli, Abdel A ^b   Vesely, Brian A ^a   Luther, Stephen L ^a   Gower Jr , William R ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Metastasis; Natriuretic peptides; New therapeutics; Pancreatic cancer; Receptors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; KALIURETIC PEPTIDE; LONG ACTING ATRIAL NATRIURETIC PEPTIDE; PEPTIDE HORMONE; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VESSEL DILATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; TUMOR VOLUME;

EID: 34250172696     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pitchumoni CS: Pancreatic disease. In: Internal Medicine. Stein JH (ed.). Louis, MO, USA, St. Mosby, pp. 2233-2247, 1998.
2. Wolff RA, Abbruzzese JL and Evans DB: Neoplasms of the exocrine pancreas. In: Cancer Medicine. Holland JF and Frei E, III (eds.). London, UK, BC Decker Inc, pp. 1436-1464, 2000.
3. Brenner BM, Ballermann BJ, Gunning ME and Zeidel ML: Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665-699, 1990.
4. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 285: F167-177, 2003.
5. Vesely DL: Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 53: 153-159, 2002.
6. Vesely BA, McAfee Q, Gower WR Jr and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
7. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR Jr and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
8. Gower WR Jr, Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′5′-cyclic monophosphate. Int J Gastrointest Cancer 36: 77-88, 2005.
9. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
10. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr and Vesely DL: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 36: 810-819, 2006.
11. Vesely BA, Fitz SR, Gower WR Jr and Vesely DL: Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 232: 226-231, 2006.
12. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli AA, Solivan SR, Gower WR Jr and Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 35: 388-398, 2005.
13. Gower WR Jr, Risch RM, Godellas CV and Fabri PJ: HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol 30A: 151-161, 1994.
14. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M, Lin R, Galipeau J and Hiscott J: In vivo interferon regulatory factor 3-tumor suppressor activity in B16 melanoma tumors. Cancer Res 62: 5148-5152, 2002.
15. Clark LC, Farghaly H, Saba SR and Vesely DL: Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am J Physiol 278: H1555-H1564, 2000.
16. Verbeke G: Linear mixed models for logitudinal data. In: Linear Mixed Models in Practice: A SAS Oriented Approach. Verbeke G, and Molenberghs G (eds.). New York, Springer-Verlag, Inc, pp. 62-153, 1997.
17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
18. Vesely DL, Cornett LE, McCleod SL, Nash AA and Norris JS: Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 11: 193-197, 1990.
19. Vesely DL, Arnold WC, Winters CJ, Sallman AL and Rico DM: Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab 71: 1138-1146, 1990.
20. Vesely DL, Sallman AL and Bayliss JM: Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons proximal tubules renal cortical and medullary membranes. Renal Physiol Biochem 15: 23-32, 1992.